Sugi Predict

Sugi Predict / Compounds / SCHEMBL3192149

SCHEMBL3192149

SCHEMBL3192149

CSc1nc2ncc(C#N)c(Nc3cccc(Cl)c3)c2s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 9/20 0.50
▸ ERBB2 P04626 5/20 0.50
▸ TOP2A P11388 2/20 0.48
▸ PRKCQ Q04759 1/20 0.43
▸ RXFP1 Q9HBX9 2/20 0.39
▸ GFER P55789 1/20 0.39
▸ CCNT1 O60563 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ CCNA1 P78396 1/20 0.38
▸ SYK P43405 1/20 0.38
▸ MAP3K8 P41279 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ STK4 Q13043 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3184527 0.88 EGFR (0.50) EGFRERBB2PRKCQ
SCHEMBL3180849 0.86 EGFR (0.52) EGFRERBB2CCNT1CCNA2CDK2
SCHEMBL3193466 0.86 EGFR (0.52) EGFRERBB2MAP3K8
SCHEMBL3193839 0.83 SRC (0.51) PRKCQSRC
SCHEMBL3180803 0.78 MAP2K1 (0.54) PRKCQSRC
SCHEMBL3182643 0.78 EGFR (0.54) EGFRERBB2
SCHEMBL3190647 0.76 SRC (0.56) PRKCQSRC
SCHEMBL3194620 0.75 SRC (0.61) SRC
SCHEMBL13481383 0.75 EGFR (0.45) EGFRERBB2
SCHEMBL3189826 0.74 KDR (0.42) NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7659284-B2 Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile JANSSEN PHARMACEUTICA NV (BE) 2010-02-09 — — US disclosed
US-7659284-B2 Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile JANSSEN PHARMACEUTICA NV (BE) 2010-02-09 — — US disclosed
US-7659284-B2 Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile JANSSEN PHARMACEUTICA NV (BE) 2010-02-09 — — US disclosed
EP-1789055-A2 THIAZOLOPYRIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-30 — — EP disclosed
WO-2006031929-A2 THIAZOLOPYRIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-03-23 — — WO disclosed
US-20060058341-A1 Thiazolopyridine kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058341-A1 Thiazolopyridine kinase inhibitors PRKACA, PRKCE, MAP3K9 EGFR 991/4885ERBB2 199/4885TOP2A 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.